The Significance of Serum S100A9 and TNC Levels as Biomarkers in Colorectal Cancer

Minze Zhou,Maoyu Li,Xujun Liang,Ye Zhang,Huichao Huang,Yilu Feng,Guoqiang Wang,Ting Liu,Zhuchu Chen,Haiping Pei,Yongheng Chen
DOI: https://doi.org/10.7150/jca.31267
IF: 3.9
2019-01-01
Journal of Cancer
Abstract:<p><b>Purpose</b>: The aim of this study was to evaluate the diagnostic value of S100A9 and tenascin-c (TNC) levels as colorectal cancer (CRC) biomarkers in several ways, including through screening tests, differentiation tests, combination with existing biomarkers (CEA and CA19-9), and serum level measurements before and after surgery.</p><p><b>Materials and Methods</b>: In this case-control study, S100A9 and TNC serum levels were measured in 460 participants: 258 CRC patients, 99 patients with benign colonic disease (BCD) and 103 healthy donors (HD).</p><p><b>Results</b>: The serum levels of S100A9 were 22.32 (14.88-29.55) ng/ml, 10.02 (5.83-14.15) ng/ml and 10.05 (7.68-15.34) ng/ml in the CRC, BCD and HD groups, respectively. The serum levels of TNC were 4.30 (2.12-6.04) ng/ml, 1.60 (1.06-2.30) ng/ml and 2.00 (1.37-3.00) ng/ml in the CRC, BCD and HD groups, respectively. Significantly higher levels of both biomarkers (S100A9 and TNC) were found in CRC patients (both p&lt;0.001).</p><p>Both S100A9 and TNC levels were superior to CEA and CA19-9 levels as CRC diagnostic biomarkers; the combination of S100A9, TNC and CEA levels was an excellent biomarker with 79.8% sensitivity and 89.6% specificity. The serum levels of S100A9 and TNC in CRC patients were significantly lower after surgery than before surgery (p&lt;0.01).</p><p><b>Conclusion</b>: S100A9 and TNC levels could serve as diagnostic biomarkers of colorectal cancer.</p>
oncology
What problem does this paper attempt to address?